These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 9113619)

  • 21. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
    Bonfig W; Bechtold S; Schmidt H; Knorr D; Schwarz HP
    J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.
    Stikkelbroeck NM; Van't Hof-Grootenboer BA; Hermus AR; Otten BJ; Van't Hof MA
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3525-30. PubMed ID: 12915631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normal adult height after steroid-withdrawal within 6 months of pediatric kidney transplantation: a 20 years single center experience.
    Klare B; Montoya CR; Fischer DC; Stangl MJ; Haffner D
    Transpl Int; 2012 Mar; 25(3):276-82. PubMed ID: 22187956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
    Pijnenburg-Kleizen KJ; Thomas CMG; Otten BJ; Roeleveld N; Claahsen-van der Grinten HL
    J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1055-1063. PubMed ID: 31573958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
    Manoli I; Kanaka-Gantenbein Ch; Voutetakis A; Maniati-Christidi M; Dacou-Voutetakis C
    Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia.
    Quintos JB; Vogiatzi MG; Harbison MD; New MI
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1511-7. PubMed ID: 11297576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.
    Lai HC; FitzSimmons SC; Allen DB; Kosorok MR; Rosenstein BJ; Campbell PW; Farrell PM
    N Engl J Med; 2000 Mar; 342(12):851-9. PubMed ID: 10727589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
    Deslauriers JR; Lenz AM; Root AW; Diamond FB; Bercu BB
    J Pediatr Endocrinol Metab; 2012; 25(9-10):977-81. PubMed ID: 23426829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GH and GnRH analog treatment in children who enter puberty at short stature.
    Tanaka T; Satoh M; Yasunaga T; Horikawa R; Tanae A; Hibi I
    J Pediatr Endocrinol Metab; 1997; 10(6):623-8. PubMed ID: 9467133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome.
    Grigorescu-Sido A; Bettendorf M; Schulze E; Duncea I; Heinrich U
    Horm Res; 2003; 60(2):84-90. PubMed ID: 12876419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia.
    Muirhead S; Sellers EA; Guyda H;
    J Pediatr; 2002 Aug; 141(2):247-52. PubMed ID: 12183722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study.
    Hargitai G; Sólyom J; Battelino T; Lebl J; Pribilincová Z; Hauspie R; Kovács J; Waldhauser F; Frisch H;
    Horm Res; 2001; 55(4):161-71. PubMed ID: 11598369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience.
    Hoepffner W; Kaufhold A; Willgerodt H; Keller E
    Horm Res; 2008; 70(1):42-50. PubMed ID: 18493149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
    Aycan Z; Ocal G; Berberoglu M; Cetinkaya E; Adiyaman P; Evliyaoglu O
    J Pediatr Endocrinol Metab; 2006 Mar; 19(3):245-51. PubMed ID: 16607925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Growth in Congenital Adrenal Hyperplasia.
    Maheshwari A; Khadilkar V; Gangodkar P; Khadilkar A
    Indian J Pediatr; 2019 Feb; 86(2):154-158. PubMed ID: 30097840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond.
    Troger T; Sommer G; Lang-Muritano M; Konrad D; Kuhlmann B; Zumsteg U; Flück CE
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e487-e499. PubMed ID: 34599587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growth curves for congenital adrenal hyperplasia from a national retrospective cohort.
    Bretones P; Riche B; Pichot E; David M; Roy P; Tardy V; Kassai B; Gaillard S; Bernoux D; Morel Y; Chatelain P; Nicolino M; Cornu C;
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1379-1388. PubMed ID: 27852974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia.
    Girgis R; Winter JS
    J Clin Endocrinol Metab; 1997 Dec; 82(12):3926-9. PubMed ID: 9398689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
    Van der Kamp HJ; Otten BJ; Buitenweg N; De Muinck Keizer-Schrama SM; Oostdijk W; Jansen M; Delemarre-de Waal HA; Vulsma T; Wit JM
    Arch Dis Child; 2002 Aug; 87(2):139-44. PubMed ID: 12138066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Endocrinologic after-care of brain tumor patients: initial retrospective analysis of HIT-study documented auxologic and endocrine parameters].
    Dŏrr HG; Koch A; Kühl J; Müller HL; Beck JD
    Klin Padiatr; 1996; 208(4):197-204. PubMed ID: 8926685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.